

Drug Use Review (DUR) Board approves changes for Physician Administered Drugs (PAD)

The Nevada Medicaid Drug Use Review (DUR) Board met on July 18, 2024, and voted to adopt the following changes to Physician Administered Drugs (PAD) criteria, effective November 4, 2024.

Drug Class/Program	Background and Explanation of Policy Changes, Clarifications and Updates
Immune Globulins (immunoglobulin)	Addition of Yimmugo®
Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1)	Additions and updates to the clinical criteria to Jemperli® and Keytruda®
Yervoy® (ipilimumab)	Additions and updates to the clinical criteria

Prior Authorization forms may be found on the below webpage:
<https://gatewaypa.com/> (medical pharmacy/physician administered drugs)